



*Better health through
laboratory medicine.*

PEARLS OF LABORATORY MEDICINE

Pearl Title: **Primary Antibody Deficiencies (PAD)**

Presenter: **Maha N. Syed MD, Joud Hajjar MD, MS**

Affiliation **Baylor College of Medicine**

DOI: 10.15428/CCTC.2018.294439



Learning Objective

- Recognize clinical patterns suggestive of Primary Antibody Deficiency (PAD)
- Learn about different presentations of PAD
- Be familiar with the diagnostic methods for PAD.
- Be familiar with common treatments used for PAD.
- Be familiar with complications caused by PAD.



Definition

- Primary antibody deficiency (PAD) syndromes are a group of rare disorders characterized by an inability to produce clinically effective immunoglobulin (Ig) responses.
- Some disorders result from genetic mutations in genes involved in B cell development, whereas others appear to be complex polygenic disorders.



Primary Antibody Deficiencies: Spectrum of disorders

- Selective IgA deficiency
- CVID (Common Variable Immune Deficiency)
- Specific antibody deficiency disorders
- Agammaglobulinemia (Both x-linked and Autosomal recessive)
- Transient hypogammaglobulinemia of infancy
- IgG subclass deficiency
- Selective IgM deficiency
- Hyper IgM syndrome



Selective IgA Deficiency (SIgAD)

- **Prevalence:** 1:400 in the Caucasian population.
- **Definition:** IgA \leq 7 mg/dl with normal IgG and IgM, normal B-cell numbers, normal specific antibody responses in most patients
- 2/3 of patients are healthy and asymptomatic.
- **Symptoms** include:
 - **Autoimmune Disorders:** (Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, Rheumatoid Arthritis, Systemic Lupus Erythematosus , Thyroiditis, and Vitiligo).
 - **Sino-pulmonary Infections:** (Encapsulated bacteria).
 - **Gastrointestinal (GI) Disorders:** (Giardiasis, nodular lymphoid hyperplasia, Celiac Disease, and Inflammatory Bowel Disease).
 - **Allergic Disease:** (Asthma, Allergic Rhinitis, Atopic Dermatitis, and food allergy).



Selective IgA Deficiency Cont'd

- Very rarely, anaphylactic transfusion reactions to plasma-containing blood products, due to presence of small amounts of IgA in blood products which reacts with anti-IgA antibodies present in such patients.
- In rare cases, Selective IgA Deficiency may progress to CVID
- Symptomatic patients should be followed longitudinally to determine if CVID develops.
- **Treatment**: Treat concomitant disorders, prophylactic antibiotics to reduce risk of infection and occasionally a trial of Immunoglobulin Replacement Therapy (IgGRT), if prophylaxis fails.



IgG Subclass Deficiency

- **Definition:** Absent/very low concentration of one or more IgG subclasses, with normal IgA, IgM and total IgG.
- Four different subtypes: IgG1, IgG2, IgG3, and IgG4
- **Symptoms:** Sinopulmonary/GI infections.
- **Diagnosis:** Total serum IgG, IgA, IgM, and IgE. IgG subclasses (obtained at initial evaluation, and only if vaccine response is impaired) Antibody titers to proteins/polysaccharide antigens like diphtheria, tetanus, *Hemophilus influenzae* type b (Hib), and *S. pneumoniae*
- **Treatment:** Prophylactic antibiotics might be considered. IgGRT reserved for patients with abnormal antibody responses and frequent or chronic infections.

Common Variable Immune Deficiency (CVID)

- Most common symptomatic primary immunodeficiency in adults
- **Prevalence**: 1:10,000 - 1: 100,000
- **Etiology**: Impaired B cell differentiation with defective Ig production
- **Symptoms**: Clinically, patients develop recurrent sinopulmonary infections. 20% of patients have non-infectious complications: autoimmunity, chronic lung/GI disease and malignancy.
- **Diagnosis**: Low IgG, IgA and/or IgM AND poor responses to protein and polysaccharide vaccines
- **Treatment**: IgGRT is the standard of care in CVID and has led to decrease in infections and improved survival.



	European Society of Immunodeficiency (ESID) 2014	International Consensus Document (ICON) 2016
Similarities	<ul style="list-style-type: none"> • IgG must be low • IgA or IgM must be low • Other causes of hypogammaglobulinemia ruled out 	
Differences	<ul style="list-style-type: none"> • Patients could have normal vaccine responses, but they should have low memory B cells (<70% of normal age range) • Clinical history of increased susceptibility to infections, autoimmunity, granulomatous disorder, unexplained polyclonal proliferation, or positive family history of PAD is required for the diagnosis • Diagnosis is established after the age of 4 years 	<ul style="list-style-type: none"> • Impaired vaccine responses must be present • The diagnosis could be established based on laboratory data, without clinical history of infections, autoimmunity, lymphoproliferation or positive family history • Onset of symptoms above 2 years of age

Specific antibody deficiency

- **Definition:** Normal IG, normal B-cell numbers, impaired specific antibody responses to polysaccharides vaccines. and *usually*, normal responses to protein based vaccines.
- **Symptoms:** Recurrent sinopulmonary infections.
- **Diagnosis:** IgG, IgG subclasses, IgA, IgM, and IgE. Vaccine response to Tetanus, Diphtheria and PneumoVax®
- **Treatment:** Prophylactic antibiotics, vaccination with conjugated pneumococcal vaccine (Prevnar), IgGRT in severe cases and failure of prophylactic antibiotics.



Polysaccharide vaccine responses



Vaccine	Phenotype	Response < 6Yr	Response > 6Yr
Pneumococcal conjugate		Normal Response 1.3 mg/mL*	protective antibodies to 70% of the serotypes tested, with at least a 2-fold increase in the titer
	Severe	≤2 protective titers (≥1.3 mcg/mL)	≤2 protective titers (≥1.3 mcg/mL)
	Moderate	<70% of serotypes are protective (≥1.3 mcg/mL)	<50% of serotypes are protective (≥1.3 mcg/mL)
	Mild	Failure to generate protective titers to multiple serotypes or failure of a 2-fold increase in 70% of serotypes	Failure to generate protective titers to multiple serotypes or failure of a 2-fold increase in 50% of serotypes
	Memory	Loss of response within 6 to 12 months	Loss of response within 6 to 12 months

* The consensus value in several studies is 1.3 mg/ml, but a value of 1.6 mg/ml has been used in other studies. Original table modified for this publication. From: Orange JS, Ballou M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the basic and clinical immunology interest section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol* 2012; 130:S1



- **Prevalence:** 1:379,000 US Live births
- **Etiology:** Failure of B-cells precursors to mature into B-cells, then plasma cells.
- **Genetics:** X-linked in 85-90% of cases, due to a mutation in the BTK* gene, Autosomal recessive in 10-15% of cases due to mutations in IGLL1**, CD79A gene BLNK^x, LRRC8^o, CD79B gene, PIK3R1 and TCF3*** gene.
- **Symptoms** Upper and lower respiratory tract by:
 - Encapsulated bacteria (*Streptococcus pneumoniae*, HiB)
 - *Mycoplasma* and *Ureaplasma* pneumonia, septic arthritis
 - *Pseudomonas* and *Staphylococcus* sepsis particularly in transient neutropenia.
 - Enterovirus infections (*polio*, *coxsackie*, *echo virus*), chronic diarrhea, meningitis, and fatal disseminated infection.
- **Diagnosis:** Agammaglobulinemia, deficient antibody responses to immunizations and absent/markedly reduced B cells in peripheral blood (CD19, CD20)
- **Treatment:** Lifetime IgGRT is indicated for all patients.

B cells phenotyping in X-Linked Agammaglobulinemia



Transient Hypogammaglobulinemia of Infancy

- **Etiology**: IgG is transferred through placenta from mother, and wears off in 3-6 months. Occasionally, infant's immune system is not mature → transient hypogammaglobulinemia.
- No inherent defects of B-cell or defects of specific antibody responses
- **Symptoms**: Recurrent sinopulmonary or GI infections, candidiasis and sometimes meningitis.
- **Laboratory**: Low IgG, variably low IgA and rarely low IgM, normal specific antibody responses in most patients, normal B-cell numbers
- **Treatment**: Patients with frequent and/or more severe infections are treated with antibiotic prophylaxis or IgGRT till Ig normalizes.



Hyper-IgM syndrome

- **Prevalence:** 1:100,000
- **Genetics:** X-linked (CD40L), or autosomal recessive (CD40, UNG*, AID^Δ)
- **Etiology:** Defects in Class-switch recombination (CSR) of Ig, with or without defects of somatic hypermutation (SHM)
- **CD40 /CD40L Deficiency:** is a combined immunodeficiency because of T cell involvement, severe infections, such as *P jirovecii* pneumonia, severe CMV disease and mucocutaneous candidiasis.
- **Complications:** failure to thrive in infants and liver disease (cirrhosis and cholangiocarcinoma)




Hyper IgM syndrome Cont'd

- **Laboratory**: Low IgG, IgA, and IgE with either normal or elevated IgM, T & B cell defects, neutropenia.
- **Treatment**: *PjP* prophylaxis, antibiotics, granulocyte colony-stimulating factor for neutropenia. immunosuppressive regimens for autoimmune manifestations. Hematopoietic cell transplantation could provide a curative option.
- **AID/UNG Deficiency**: Less common form of Hyper IgM. Characterized by recurrent sinopulmonary infections, mostly due to encapsulated bacteria, lymphoid hyperplasia, tonsillar hypertrophy, autoimmunity and malignancy



Normal switched memory B cell



Selective IgM Deficiency

- **Definition:** Absent/very low IgM and normal IgG/IgA.
- Associated with Autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, celiac disease, polymyositis, and Hashimoto's thyroiditis.
- **Symptoms:** Sinopulmonary infections, most commonly seen in children. Adults present with allergies and autoimmunity in addition to these infections.
- **Laboratory:** Low or absent IgM and normal IgA, IgG, normal or impaired response to vaccines. Ruling out other conditions causing low IgM.
- **Treatment:** No commercially available highly enriched IgM preparation. Treatment with IgGRT maybe considered in those with selective antibody deficiency and recurrent infections.



Laboratory evaluation of Humoral Immune Deficiency


- Targeted History & Physical exam for recurrent infections and autoimmunity
- Quantitative serum Ig (age and sex matched controls)
- Measurement of Antibody production
 - Polysaccharide vaccine, PneumoVax®
 - Protein based: Tetanus, Diphtheria
 - 4 week post-immunization level within protective range, cut off varies with each vaccine. (See Orange et al. 2012)
- Peripheral blood lymphocyte subset analysis



Selected CD markers used in PAD diagnosis

T-cells	CD3
CD4	CD4 (CD3 ⁺ CD4 ⁺)
CD8	CD8 (CD3 ⁺ CD8 ⁺)
B-Cells	CD19 (CD3 ⁻ CD19 ⁺)
Memory B-cell	CD19 ⁺ CD27 ⁺
Non-switched memory B-cells	CD19 ⁺ CD27 ⁺ IgM ⁺ IgD ⁺
Switched memory B-cells	CD19 ⁺ CD27 ⁺ IgM ⁻ IgD ⁻
Transitional B cells	CD19 ⁺ CD38 ^{bright}
Activated/autoimmune B cells	CD19 ⁺ CD38 ^{-/low} CD21 ^{-/low}

Figure 1. Evaluation of PAD*



1. Immune Deficiency Foundation website: <http://www.primaryimmune.org/>
2. <https://uptodate.com>
3. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. *J Allergy Clin Immunol*. 2006 Apr;117(4 Suppl):S525-53.
4. Bonilla FA, Khan DA, Ballas ZK, Chinen J. Practice parameter for the diagnosis and management of primary immunodeficiency. *Ann Allergy Asthma Immunol*. 2005 May;94(5 Suppl 1):S1-63.
5. Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. *Eur J Pediatr* 170: 693-702, 2011.
6. Conley ME, Dobbs AK, Farmer DM et al. Primary B cell immunodeficiencies: comparisons and contrasts *Annu Rev Immunol* 27: 199–227, 2009.
7. Cunningham-Rundles C. Human B cell defects in perspective. *Immunol Res* 54: 227-32, 2012.
8. Abraham RS. Relevance of antibody testing in patients with recurrent infections. *J Allergy Clin Immunol* 130: 558-9, 2012.
9. Wood P. Primary antibody deficiency syndromes. *Ann Clin Biochem*. 2009 Mar;46(Pt 2):99-108. Epub 2009 Jan 16
10. Uygungil B, Bonilla F, Lederman H. Evaluation of a patient with hyper-IgM syndrome. *J Allergy Clin Immunol* 129:1692-3, 2012.
11. Yong PF, Thaventhiran JE, Grimbacher B "A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011 *Adv Immunol* 111:47-107, 2011.
12. Yel L. Selective IgA deficiency. *J Clin Immunol* 30:10-6, 2010.
13. Krishnaswamy G. Selective IgM deficiency. UpToDate. Waltham, MA: UpToDate; July 26, 2017; <http://www.uptodate.com/contents/selective-igm-deficiency>.
14. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. *Clin Microbiol Rev*. 2009 Jul;22(3):396-414.
15. Cherry J, Demmler-Hariison GJ, Kaplan SL, Steinbach WJ, Feigin and Cherry's textbook of pediatric infectious diseases. Seventh Edition. 2009.
16. Louis, A.G. Gupta, S. Primary selective IgM deficiency: an ignored immunodeficiency. *Clinic Rev Allerg Immunol* (2014) 46: 104. <https://doi.org/10.1007/s12016-013-8375-x>
17. Orange JS1, Ballou M, Stiehm ER et al Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol*. 2012 Sep;130(3 Suppl):S1-24. doi: 10.1016/j.jaci.2012.07.002
18. Ameratunga R, Brewerton M, Slade C, et al Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorder, *Front Immunol*. 2014; 5: 415.
19. Bonilla FA, Barlan I, Chapel H, et al, International Consensus Document (ICON): Common Variable Immunodeficiency Disorders, *J Allergy Clin Immunol Pract*. 2016 Jan-Feb; 4(1): 38–59.

Disclosures/Potential Conflicts of Interest

Upon Pearl submission, the presenter completed the Clinical Chemistry disclosure form. Disclosures and/or potential conflicts of interest:

- **Employment or Leadership:** No disclosures
- **Consultant or Advisory Role:** No disclosures
- **Stock Ownership:** No disclosures
- **Honoraria:** No disclosures
- **Research Funding:** No disclosures
- **Expert Testimony:** No disclosures
- **Patents:** No disclosures



Thank you for participating in this
Clinical Chemistry Trainee Council
Pearl of Laboratory Medicine.

Find our upcoming Pearls and other
Trainee Council information at
www.traineecouncil.org

Download the free *Clinical Chemistry* app
on iTunes today for additional content!

Follow us:

